Jyske Realkredit A/S
23.2.2021 10:47:41 CET | Globenewswire | Press release
To Nasdaq Copenhagen A/S 23 February 2021
Announcement no. 23 /2021
New base prospectus for covered bonds, mortgage bonds and bonds issued pursuant to Section 15 of the Danish Mortage-Credit Loans and Mortgage-Credit Bonds etc. Act
Jyske Realkredit hereby publish a new base prospectus for covered bonds, mortgage bonds and bonds issued pursuant to Section 15 of the Danish Mortage-Credit Loans and Mortgage-Credit Bonds etc. Act – Base Prospectus dated 23 February 2021.
Jyske Realkredit’s Base Prospectus and any Addenda are available for download in Danish and English on Jyske Realkredit’s website www.jyskerealkredit.com. Jyske Realkredit’s Base Prospectus dated 23. February 2021 is also enclosed this announcement.
For more information, please contact:
- Head of Rating and IR, Christian Bech-Ravn on telephone (+45) 89 89 92 25
- Legal Counsel Berit Fredberg on telephone (+45) 89 89 79 64
Yours sincerely
Jyske Realkredit
Søren Winkler
Senior Director
Please observe that the Danish version of this announcement prevails
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S2.10.2026 19:49:50 CEST | Press release
Major Shareholder Announcement
HENLEY & PARTNERS GROUP HOLDINGS LTD2.10.2026 18:54:53 CEST | Press release
Henley & Partners - Argentina Announces New Citizenship by Investment Program
Unlimit Group A/S2.10.2026 18:05:13 CEST | Pressemeddelelse
Unlimit Group A/S: Indkaldelse til ekstraordinær generalforsamling
BONDUELLE2.10.2026 18:00:00 CEST | Press release
Bonduelle - 2025-2026 Annual results: The Bonduelle Group demonstrates its resilience, ending fiscal year 2025-2026 with stable sales and profitability
Biogen Inc.2.10.2026 17:20:00 CEST | Press release
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
